CoChat

Gene Therapy 2017: Progress and Future Directions

Open access
Keeler, AM, ElMallah, MK, Flotte, TR · 2017 · Clinical and Translational Science
Cited by 133

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Gene therapy has changed dramatically in the 28 years since the first human gene transfer experiment in 1989.Alipogene tiparvovec, GlyberaR R , a recombinant adenoassociated virus (rAAV) product for lipoprotein lipase deficiency, and Strimvelis R , a lentivirus vector for severe combined immune deficiency are approved in Europe.An rAAV2 product for a congenital form of blindness is currently under review in the United States, likely to be followed by numerous other gene therapies. Nonviral gene transferThe success of gene therapy has largely been driven by improvements in nonviral and viral gene transfer vectors.An array of physical and chemical nonviral methods have been used to transfer DNA and mRNA to mammalian cells and a substantial number of these have been developed as clinical stage technologies for gene therapy, both ex vivo and in vivo.Cationic liposome technology is based on the ability of amphipathic lipids, possessing a positively charged head group and a hydrophobic lipid tail, to bind to negatively charged DNA or RNA and form particles that generally enter cells by endocytosis.Some cationic liposomes also contain a neutral co-lipid, thought to enhance liposome uptake by mammalian cells.[4][5][6][7] Similarly, other polycations, such as poly-l-lysine and polyethylene-imine, complex with nucleic acids via charge interaction and aid in the condensation of DNA or RNA into nanoparticles, which are then substrates for endosome-mediated uptake.8 Several of these cationicnucleic acid complex technologies have been developed as potential clinical products, including complexes with plasmid DNA (pDNA), oligodeoxynucleotides, and various forms of synthetic RNA.[9][10][11] Modified (and unmodified or "naked") DNA, RNA, and oligonucleotides have also been shown to mediate successful gene transfer in a number of circumstances.These include the use of pDNA by direct intramuscular injection for DNA vaccines, the use of intratumoral injection of pDNA to deliver cytokine and/or suicide genes, systemic (s.c. or i.v.) injection of antisense nucleotides to induce RNAse H1 or exon-skipping.[12][13][14] The most recent of these developed for induction of RNAi are discussed in a later section.Ex vivo introduction of pDNA and/or other nucleotides using physical methods has been well developed for certain

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cts.12466

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 133

Metadata

Authors
Keeler, A., ElMallah, M., & Flotte, T.
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2017-05-23
Volume
10
Issue
4
Pages
242-248
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W2604759168
Cited by
133
References
33
FWCI
13.75
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Therapy 2017: Progress and Future Directions. https://app.cochat.ai/papers/10.1111/cts.12466
The paper
Keeler, A., ElMallah, M., & Flotte, T. (2017). Gene Therapy 2017: Progress and Future Directions. Clinical and Translational Science. https://doi.org/10.1111/cts.12466

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.